A comprehensive characterization of lung adenocarcinoma (LADC) clinical features is currently missing. We prospectively evaluated Caucasian patients with early-stage LADC. Patients with LADC diagnosed between 2011 and 2015 were prospectively assessed for lung resection with curative intent. Fifty clinical, pathologic, radiologic, and molecular variables were recorded. Patients were followed till death/study
| INTRODUCTION
Lung adenocarcinoma (LADC) is the most frequent histologic type of lung cancer. 1, 2 It constitutes the most deadly human cancer, causing 650 000 deaths per year worldwide, 3, 4 while its incidence is increasing in active smokers, ex-smokers, and never-smokers. 5 Simultaneously, LADC is the most frequent lung cancer in never-smokers, women, and young patients, rendering understanding and treating the disease imperative. 5, 6 LADC is mainly caused by smoking, radiation, and other exposures. 5, 7 Although multiple approaches to prevention/early detection have been evaluated, only 15% of patients diagnosed with LADC are amenable to surgery, the only definitive cure. 8 These patients are of tremendous importance, since they donate tissues for research that has fostered our understanding of the pathobiology of locoregional LADC and has enabled targeted therapies for patients with defined oncogenic driver mutations. 9, 10 Recent molecular evidence indicates LADC to be a distinct disease entity. 11 However, the clinical gestalt of the disease has not been comprehensively characterized separately from other forms of lung cancer. Here we report the first results from the Gauting locoregional lung adenocarcinoma donors (GLAD) study, a prospective biobank of LADC tissues and clinical phenotypes. The wealth of clinical information provided includes multiple variables and prolonged follow-up data, enabling the discovery of new associations reported here, as well as the future establishment of genotype-phenotype links.
| MATERIAL AND METHODS

| Studies approval
GLAD was conducted in accord with the Helsinki Declaration, reported in accord to STROBE (https://www. strobe-statement.org/index.php?xml:id=strobe-home), approved by the LMU Ethics Committee (623-15), registered with the German Clinical Trials Register (http://www.drks.de/ drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ ID=DRKS00012649), and written informed consent was obtained from all patients (https://www.asklepios.com/gauting/ experten/experten/biobank/). The Tours study was conducted according to the Helsinki Declaration, was approved by the Ethics Committee of Région Centre (2015/051), and was registered with the French Ministry of Health (DC-2008-308). All patients gave written informed consent.
| GLAD study
All patients with histologic LADC diagnosis at Asklepios Medical Center between February 2011 and September 2015 were prospectively evaluated for lung resection with curative intent. LADC was staged according to the current Seventh Edition of the International Association for the Study of Lung Cancer (IASLC) tumor-node-metastasis staging system (TNM7). 2 Preoperative lung function was assessed according to current guidelines. 12 The Absolute
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conclusion. 3 | RESULTS
| The Gauting locoregional lung adenocarcinoma donors (GLAD)
During the period from February 2011 to September 2015, 1943 patients with LADC were prospectively assessed in the Asklepios Medical Center, Gauting, Germany. Among them, 455 were eligible and fit for curative surgery, and 366 were enrolled (89 patients were excluded due to cTNM7 N3 disease or unwillingness to provide informed consent). They represent ~28% of registered Bavarian locoregional LADC cases during the study period (21 588 lung cancer cases, corresponding to 8635 LADC cases at expected 40%, and to 1295 resectable LADC cases at expected 15%; http://www.krebsregister-bayern.de/index_e.html) summarized in Figure 1A . [16] [17] [18] During the same period, another 1577 patients with LADC were not eligible or fit for lung resection, rendering 23% of patients screened resectable with intention to treat, and resulting in 19% recruitment rate into GLAD ( Figure 1B and C). Of the 366 patients resected, 41 had oligometastatic disease detected prior to surgery, seven were incompletely resected, and in 20 a malignant pleural disease was identified intraoperatively. Out of the 305 patients that were tumor-free after surgery, 301 remained tumor-free at the 30-day postoperative census (82.2%), and 181 (49.5%) at the mid-2016 census ( Figure 1D ). At this time, 8453 cumulative follow-up months (median[interquartile range, IQR] 18 months/patient) had been delivered, and 120 relapses and 74 deaths were observed. Median(95% confidence interval, CI) overall survival (OS) was not reached (>7.5 years), disease-free survival (DFS) was 3.64 (2.76-5.88) years, and 5-year OS and DFS rates were 62% and 39%, respectively ( Figure 1E ). GLAD will be re-censored mid-biannually; hence survival data are expected to evolve. A color-coded phenome plot of all information available at the mid-2016 census is shown in Figure 2 and Table S1 , while a heat map of all the associations observed (discussed below) is given in Figure 3 . The major findings from GLAD classified according to clinical variables are presented below.
| Age
In GLAD, median(IQR) age was 67 (59-72) years, including 11 (3%) and 195 (53%) patients younger than 45 and older than 65 years, respectively; those had markedly decreased overall survival (OS) and disease-free survival (DFS) compared with 160 (44%) patients aged between 45 and 65 years ( Figure 4A and B). Age was positively associated with cumulative smoke exposure and lepidic/papillary histology. On the contrary, it was negatively linked with current smoking, body length, FVC and FEV 1 , and time to surgery (Figure 3 ). In addition, more death and relapse events were observed in patients of extreme age (<45 or >65 years) ( Figure S1A ). Linear regression-calculated lung function decline rates with age were similar to the Framingham study, 19 and lung function test results were tightly correlated with body metric indices, validating GLAD lung function data ( Figure S1B-D) . Interestingly, patients with affected resection margins and perioperative pleural relapse were significantly younger ( Figure S1A ).
| Sex
Surprisingly, 181 patients (49.5%) of GLAD were female, reflecting increasing local and worldwide female smoking trends. 6, 20 Female sex was positively associated with percent predicted FVC and FEV 1 values and FEV 1 /FVC ratio, and negatively linked with smoking rate and intensity, body metric indices, absolute FVC and FEV 1 and percent predicted DL CO /V A , COPD frequency, solid histologic subtype, and adrenal relapse ( Figure S2 ). However, sex did not significantly impact survival ( Figure 4B ). These results suggested that locoregional LADC in Caucasian women has distinct features as proposed elsewhere. 6 However, these do not profoundly alter the biologic course of the disease, in accord with published results from Norway. 
| Smoking
The GLAD study included 75 never (20.5%), 130 former (35.5%), and 161 current (44.0%) smokers. Alarmingly, active smokers were younger ( Figure 4C ). Smoking abstinence of ex-smokers was median(IQR) = 10(5-25) years. Importantly, more than 50% of patients were never/exsmokers ( Figure 1A ). GLAD smoking rates were disproportional to a Norwegian cohort of 54 never (7.8%), 255 former (36.8%), and 383 current (55.3%) smokers (P < 0.0001 21 Hence the Tours cohort was identified as an optimal comparison set ( Figure S3 , Table S2 ). Expectedly, current smoking was significantly more frequent (P = 0.0044, χ 2 test) in GLAD (44%) compared with current Bavarian rates (24.2%) ( Figure 4D ). 17 Median(IQR) pack-years smoked were 40 (9-60), and smoking exposure correlated negatively with lung function, especially DL CO /V A ( Figure S4A-C) . Moreover, in accord with published results, 22 active smoking was associated with solid, and never smoking with acinar histology ( Figure S4D ). Interestingly, smoking was negatively associated with N stage, postoperative pleural relapse, as well as bone metastasis ( Figure S4D ). 9 However, smoking did not affect survival ( Figure S4E and F Figure 2 ). Smoking was intimately linked with GOLD COPD stage (P < 0.0001, Fisher's exact test) and COPD was significantly more prevalent in GLAD compared with current Bavarian rates (P < 0.0001, Fisher's exact test; Figure 4D and E). 18 These findings were validated using real-time statistics (https://knoema.com/REG_DEMO_ TL2/demographic-statistics?region=1001010-bavaria, http://www.registrecancers59.fr/index.php/incidence) in GLAD and Tours cohorts ( Figure 1A , Figure S3A ), 24 underpinning the causative role of smoking in both COPD and LADC. 25 Lung function tests were concordant to GOLD COPD definition ( Figure S5A ). COPD was positively associated with affected resection margins and perioperative pleuropulmonary relapse likely attributable to adverse effects of distorted lung structure on surgical outcome, and correlated negatively with FVC and DL CO /V A ( Figure S5B ). However, COPD did not impact survival ( Figure S5C and  D) . Of all lung function variables, only abnormal percentage predicted FVC and DL CO /V A negatively impacted survival ( Figure S5E and F) . Collectively, the data indicate that COPD and LADC show significant overlap, suggesting a common pathogenesis, in line with the literature. 25 Moreover, the percentage predicted FVC and DL CO /V A , but not other spirometry indices or a diagnosis of COPD, can predict survival.
| cTNM7 staging
All patients were staged according to cTNM7 to guide management. 2, 14 We included history, physical exam, and chest-toadrenal computed tomography in all. For stage III patients, an invasive bronchoscopy with mediastinal lymph node sampling, mediastinoscopy, and/or 18 fluoro-deoxyglucose positron emission tomography were also performed. Analysis of T, N, and cTNM7 stage showed a significant impact on survival ( Figure  S6 ) and validated GLAD against the reference IASLC study. 
| Surgery
Time from imaging/tissue diagnosis to surgery was median(IQR) = 6 (0-25) days. Resection within 60 days was achieved in 337 patients (92%), while 29 (8%) had resections performed >60 days after diagnosis. Out of 366 GLAD patients, 58 had preexisting oligometastatic, N3 disease, or pleural dissemination newly identified at surgery, leaving 308 for resection with intent-to-treat. Complete resection was achieved in 301 of these patients (97.7%; P = 0.8639, Fisher's exact test). Importantly, time to surgery significantly affected overall and disease-free survival ( Figure 4F ).
| Tumor location
The lobe of origin of GLAD tumors was definitively determined during surgery in 296 patients, while tumors involving multiple lobes, central airways, and/or mediastinal structures rendered this impossible in 70 patients. We identified a striking upper lobe predominance in both GLAD and Tours cohorts, which was disproportional to published lobe ventilation or perfusion patterns, and was reminiscent of lobar ventilation/ perfusion ratios ( Figure 4G-I) . 26, 27 Strikingly, RUL LADCs predominated in smokers of both cohorts, and patients with RUL LADC displayed higher FVC, FEV 1 , and N stage, but similar survival, compared with all other patients ( Figure S7 ). lepidic-predominant tumors in LADC was more frequent in never-smokers and displayed lower overall TNM descriptors, decreased metastatic propensity, and prolonged overall survival, as opposed to solid-predominant LADC that displayed aggressive features and poor survival ( Figure  S8 ), further validating GLAD.
| Histology
| Patterns of relapse
Over 704 cumulative follow-up years, 190 relapse events were identified in 120 patients ( Figure 1D ). In addition to the associations described above, patients with higher cTNM7 descriptors had higher relapse rates, both at the with multiple relapses also had pleural relapse) adversely impacted DFS indicating that pleural relapse occurs earlier than others ( Figure S9 ).
F I G U R E 5 Development of the locoregional lung adenocarcinoma death risk score (LADERS) from the GLAD derivation cohort. (A)
Results of least absolute shrinkage and selection operator (LASSO) regression. Shown are regression coefficients for overall (OS) and disease-free (DFS) survival and color-coded direction of impact on survival. (B) Results of Cox regression showing proportional hazards survival plots for the six independent predictors of survival of GLAD, including sample sizes (n) and probability values (P). (C) Schematic representation of the components and relative weight of the variables that comprise LADERS compared with the TNM staging system, including χ 2 probability value (P). FVC, forced vital capacity; FEV 1 , forced expiratory volume in 1 seconds; DL CO , uncorrected lung diffusion capacity for carbon monoxide; V A , alveolar ventilation; GOLD, global initiative for chronic obstructive lung disease; COPD, chronic obstructive pulmonary disease; TNM, tumornode-metastasis staging system; p, pathologic 
| Survival
We next assessed the impact of each variable on OS and DFS. In a first step, Kaplan-Meier analyses using OS and DFS as target and single variables as inputs (continuous numerical variables were dichotomized at abnormal cutoffs) showed that patients with age outlying 45-65 years, abnormal percentage predicted FVC and DL CO /V A , high T, N, and cTNM7 descriptors, delayed and incomplete resection, solid histologic subtype, and pleural relapse; had decreased OS and/or DFS ( Figures 4A and 4F, Figures S5E and F, S6, S8C and D, S9B). All variables were entered into a second line least absolute shrinkage and selection operator (LASSO) regression analysis that identified age, body mass, percentage predicted FVC, FEV 1 /FVC ratio, percentage predicted DL CO , GOLD COPD stage, T, N, and cTNM7 stage, time to surgery, right lower lobe origin, and histologic subtype as determinants of OS and/or DFS ( Figure 5A ). In a final step, all variables that emerged both from Kaplan-Meier and LASSO analyses were entered into Cox regression using backward Waldman elimination, which identified age outlying 45-65 years, abnormal percentage predicted FVC and DL CO /V A , N2/3 disease, delayed resection, and solid histology as independent predictors of OS of GLAD ( Figure 5B ).
| The locoregional lung adenocarcinoma death risk score (LADERS)
We next built a model to predict OS at the 30-day postresection benchmark, using the six variables that withstood Kaplan-Meier, LASSO, and Cox regression testing using OS as the target. LADERS employs Cox proportional hazard points and was tailored for easy clinical use without extra imaging/procedures ( Figures 5C and 6A and B, Table 1 ). LADERS displayed only 25% correlation with pTNM7 and was intimately linked with death events, while pTNM7 showed tight linkage with relapse events (Figure S10A and B). LADERS outperformed pTNM7 in predicting OS of GLAD in Kaplan-Meier and Cox regression analyses, while pTNM7 performed better in predicting DFS ( Figure S10C ; Table 2 ). LADERS also outperformed pTNM7 in predicting OS in the Tours cohort ( Figure 6C and D) .
| DISCUSSION
Here we present GLAD, a prospectively evolving biobank of phenotypes and tumor/normal paired tissues of patients with locoregional LADC. The longitudinal follow-up of the cohort suggests that locoregional LADC is currently a chronic lung disease with median survival >7.5 years. We corroborate pertinent findings of previous studies, such as the high frequency of these tumors in never/ex-smokers and women and the significant overlap of LADC with COPD, the upper lobe predominance of these tumors that appears to be dexterous in smokers, as well as the value of current staging and histologic typing systems in management and prognosis. 1, 2, 22 Using detailed phenotyping and prolonged follow-up, we discovered previously ill-defined and undefined clinical associations, such as the adverse effects of extreme age, poor lung function, and delayed resection on survival, as well as the early nature of pleural and the latency of pulmonary relapse. Most of our findings are corroborated in a separate patient cohort from France. Most importantly, we combined this wealth of clinical information to produce LADERS, a clinical score that accurately predicts survival in both cohorts. In accord with only one previous report, 28 young GLAD patients developed more aggressive LADC, possibly attributable to germline tumor suppressor loss, a hypothesis that can be directly tested in GLAD tissues. On the other hand, extremely old patients appeared to have a worse surgical prognosis associated with reduced lung and overall function. Active smokers had low N stage and relapse rates, findings possibly related with the young age and increased surveillance of active smokers in our cohort.
For the first time, we report how important time to surgery is for incipient survival, underscoring the aggressiveness of the disease and the urgency of surgery. We also define a previously reported spatial pattern of LADC development in the upper lobes. 29 Although the clinical importance of this finding is unclear, it is likely the result of increased local conversion of inhaled precarcinogens to active carcinogens in the upper lobes of smokers. Of special note, we identify distinct temporal trends in organ-specific relapse of early-stage LADC, similar to biphasic metastatic patterns of other tumor types like breast cancer. 30 Importantly, we provide clinicians with LADERS, an easy-to-use and accurate clinical tool to predict survival.
In conclusion, the first results from a prospective cohort of patients with locoregional LADC corroborate the impact of current staging and histologic subtyping systems and identify important effects of age, lung function, and time to resection on survival. A clinical tool to assess survival is also provided. Importantly, future combination of clinical information with tissue profiling is anticipated to unveil novel tumor genomephenome links and unprecedented mechanistic insights into evolution of carcinogenesis in the respiratory tract.
T A B L E 2 Performance of pTNM7 and LADERS scores as predictors of survival of GLAD patients at discharge from thoracic surgery 
